Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 18, 2023

Overall Survival in Patients With HR+/HER2− Metastatic Breast Cancer Receiving CDK4/6 Inhibitors in Addition to Endocrine Therapy



Additional Info

Disclosure statements are available on the authors' profiles:

Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study
Cancer 2023 Feb 09;[EPub Ahead of Print], RK Goyal, H Chen, SM Abughosh, HM Holmes, SD Candrilli, ML Johnson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading